| Angela Louise Guzzardo, CNM | |
|
530 N 108th Pl, Wauwatosa, WI 53226-4253 | |
| (414) 231-9640 | |
| Not Available |
| Full Name | Angela Louise Guzzardo |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 530 N 108th Pl, Wauwatosa, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790453710 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 149011-32 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Louise Guzzardo, CNM 2821 N 83rd St, Milwaukee, WI 53222-4821 Ph: (262) 215-3708 | Angela Louise Guzzardo, CNM 530 N 108th Pl, Wauwatosa, WI 53226-4253 Ph: (414) 231-9640 |
News Archive
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.
Proteasome inhibitors have significant promise as components of novel combination therapies to treat multidrug-resistant malaria, according to a study published June 6 in the open-access journal PLOS Pathogens by David Fidock, Caroline Ng, and Barbara Stokes of Columbia University Irving Medical Center, Matthew Bogyo of Stanford University School of Medicine, and colleagues.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.
Newcastle researchers have developed a genetic test providing a rapid diagnosis of mitochondrial disorders to identify the first patients with inherited mutations in a new disease gene.
Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
› Verified 2 days ago
Sarah Catherine Jones, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 530 N 108th Pl, Wauwatosa, WI 53226 Phone: 414-231-9640 | |
Alice M Phipps, CNM, NP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 530 N 108th Pl Ste 100, Wauwatosa, WI 53226 Phone: 414-231-9640 |